NCT03733210 2023-05-19
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Stanford University
Phase 1 Completed
Clinical Trials
12 trialsNCT03360734 2021-07-12
GATTO
Glycotope GmbH
Phase 1 Completed
NCT02008383 2021-02-12
CaboMAb
Duke University
Phase 1 Completed
NCT01061788 2019-08-28
RAP
Duke University
Phase 1 Completed
NCT00610948 2017-05-04
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00513383 2017-03-01
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Massachusetts General Hospital
Phase 1 Completed
NCT00658658 2016-05-18
Panitumumab in Children With Solid Tumors
Amgen
Phase 1 Completed
NCT00563316 2016-04-12
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Amgen
Phase 1 Completed
NCT00586443 2014-11-19
BEP
Duke University
Phase 1 Completed
NCT00004879 2013-01-08
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00101894 2012-09-17
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Amgen
Phase 1 Completed
NCT00091806 2009-07-10
Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed